SG11201404532XA - Pseudomonas aeruginosa pcrv binding single variable domain antibodies - Google Patents

Pseudomonas aeruginosa pcrv binding single variable domain antibodies

Info

Publication number
SG11201404532XA
SG11201404532XA SG11201404532XA SG11201404532XA SG11201404532XA SG 11201404532X A SG11201404532X A SG 11201404532XA SG 11201404532X A SG11201404532X A SG 11201404532XA SG 11201404532X A SG11201404532X A SG 11201404532XA SG 11201404532X A SG11201404532X A SG 11201404532XA
Authority
SG
Singapore
Prior art keywords
variable domain
pseudomonas aeruginosa
single variable
domain antibodies
binding single
Prior art date
Application number
SG11201404532XA
Other languages
English (en)
Inventor
Tavernier Evelyn De
Ann Union
Bruno Dombrecht
Guy Hermans
Erika Morizzo
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of SG11201404532XA publication Critical patent/SG11201404532XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
SG11201404532XA 2012-03-02 2013-03-04 Pseudomonas aeruginosa pcrv binding single variable domain antibodies SG11201404532XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261606094P 2012-03-02 2012-03-02
PCT/EP2013/054262 WO2013128031A1 (fr) 2012-03-02 2013-03-04 Anticorps à domaine variable unique se liant à la protéine pcvr de pseudomonas aeruginosa

Publications (1)

Publication Number Publication Date
SG11201404532XA true SG11201404532XA (en) 2014-08-28

Family

ID=47757633

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201404532XA SG11201404532XA (en) 2012-03-02 2013-03-04 Pseudomonas aeruginosa pcrv binding single variable domain antibodies

Country Status (12)

Country Link
US (2) US10072098B2 (fr)
EP (1) EP2820043B1 (fr)
JP (2) JP6415987B2 (fr)
KR (1) KR20140132748A (fr)
CN (1) CN104144945A (fr)
AU (1) AU2013224851B2 (fr)
CA (1) CA2863468A1 (fr)
MX (1) MX2014010495A (fr)
PH (1) PH12014501818A1 (fr)
RU (1) RU2014139911A (fr)
SG (1) SG11201404532XA (fr)
WO (1) WO2013128031A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6182152B2 (ja) * 2011-11-07 2017-08-16 メディミューン，エルエルシー 抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）ＰｓｌおよびＰｃｒＶ結合分子を用いた併用治療
MX2014010495A (es) * 2012-03-02 2014-11-14 Ablynx Nv Polipeptidos que enlazan a pcrv.
MX2016008355A (es) * 2013-12-23 2016-10-28 Zymeworks Inc Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos.
MX2017014002A (es) * 2015-05-01 2018-08-01 Inhibrx Lp Moléculas de direccionamiento del sistema de secreción tipo iii .
PL3322734T3 (pl) 2015-07-16 2021-05-04 Inhibrx, Inc. Wielowartościowe i wielospecyficzne białka fuzyjne wiążące się z DR5
GB201518668D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
CN105732817B (zh) * 2016-03-02 2019-11-08 中国人民解放军第三军医大学 一种铜绿假单胞菌重组蛋白Vac33及制备方法和应用
SG11201809778TA (en) * 2016-05-05 2018-12-28 Univ Pennsylvania Dna antibody constructs for use against pseudomonas aeruginosa
JP7478807B2 (ja) * 2019-07-09 2024-05-07 北京三▲諾▼佳邑生物技▲術▼有限▲責▼任公司 シュードモナス菌ＰｃｒＶを特異的に認識する抗体及びその使用
WO2024133935A1 (fr) 2022-12-23 2024-06-27 Ablynx Nv Excipients de conjugaison protéiques
WO2024170756A1 (fr) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides se liant au récepteur fc néonatal
CN118440191A (zh) * 2024-05-11 2024-08-06 重庆原伦生物科技有限公司 一种抗铜绿假单胞菌PcrV抗体的制备及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991015581A1 (fr) 1990-04-05 1991-10-17 Roberto Crea Mutagenese 'traversante'
DK1353688T3 (da) * 2001-01-26 2007-04-10 Mcw Res Found Inc Fremgangsmåde og sammensætninger til immunisering med Psedomonas V-antigenet
US20050136428A1 (en) 2003-06-27 2005-06-23 Roberto Crea Look-through mutagenesis
ES2372503T3 (es) 2004-07-06 2012-01-20 Bioren, Inc. Mutagénesis revisada para desarrollar polipéptidos alterados con propiedades potenciadas.
US8211648B2 (en) * 2005-07-22 2012-07-03 Kalobios Pharmaceuticals, Inc. Secretion of antibodies without signal peptides from bacteria
EP2086998B1 (fr) 2006-10-11 2011-12-07 Ablynx N.V. Sequences d'acides amines se liant a des proteines seriques essentiellement independamment du ph, composes comprenant celles et utilisations correspondantes
WO2009073631A2 (fr) 2007-11-30 2009-06-11 Kalobios Pharmaceuticals, Inc. Anticorps dirigés contre l'antigène pcrv de pseudomonas aeruginosa
AU2009203426C1 (en) * 2008-01-10 2012-05-31 Shionogi & Co., Ltd. Antibody directed against PcrV
WO2010066835A2 (fr) 2008-12-10 2010-06-17 Ablynx Nv Interaction des récepteurs eph et des ligands ephrin
JP6182152B2 (ja) * 2011-11-07 2017-08-16 メディミューン，エルエルシー 抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）ＰｓｌおよびＰｃｒＶ結合分子を用いた併用治療
JP2014533249A (ja) * 2011-11-07 2014-12-11 メディミューン，エルエルシー 多重特異性を持つ多価結合タンパク質およびその使用
MX2014010495A (es) 2012-03-02 2014-11-14 Ablynx Nv Polipeptidos que enlazan a pcrv.

Also Published As

Publication number Publication date
PH12014501818A1 (en) 2014-11-17
US20150044215A1 (en) 2015-02-12
KR20140132748A (ko) 2014-11-18
US20200190217A9 (en) 2020-06-18
US10072098B2 (en) 2018-09-11
EP2820043B1 (fr) 2020-01-15
EP2820043A1 (fr) 2015-01-07
JP2015509723A (ja) 2015-04-02
MX2014010495A (es) 2014-11-14
AU2013224851B2 (en) 2018-03-01
CA2863468A1 (fr) 2013-09-06
JP2019013239A (ja) 2019-01-31
US20190055322A1 (en) 2019-02-21
AU2013224851A1 (en) 2014-08-28
WO2013128031A1 (fr) 2013-09-06
JP6415987B2 (ja) 2018-10-31
US11312788B2 (en) 2022-04-26
RU2014139911A (ru) 2016-04-20
JP7007250B2 (ja) 2022-02-10
CN104144945A (zh) 2014-11-12

Similar Documents

Publication Publication Date Title
HRP20181646T1 (hr) Konjugati pirolobenzodiazepin - anti-psma protutijela
SG11201404532XA (en) Pseudomonas aeruginosa pcrv binding single variable domain antibodies
HK1249123A1 (zh) 共價連接的抗原-抗體綴合物
ZA201502267B (en) Pyrrolobenzodiazepine-anti-her2 antibody conjugates
AU2013355931A1 (en) Anti-folr1 antibody
EP2875128B8 (fr) Hélicases modifiées
EP2917360A4 (fr) Anticorps dirigés contre des déterminants de surface de s. aureus
PL2906251T3 (pl) Koniugaty pirolobenzodiazepina-przeciwciało anty-CD22
EP2647955B8 (fr) Annulation du déphasage de quadrature de dispositif MEMS
HK1214281A1 (zh) 具有降低的與抗藥物抗體結合的經修飾的單可變結構域抗體
HK1201453A1 (en) Combination therapies using anti- pseudomonas psl and pcrv binding molecules psl pcrv
BR112014028222A2 (pt) conjugados vinculadores auto-estabilizantes.
EP2850267B8 (fr) Dispositif de charnière équilibrée avec frein programmable
AP2015008266A0 (en) 1L-18 binding molecules
HK1202556A1 (en) Single domain binding molecule
EP3061818A4 (fr) Anticorps anti-lps o11
IL235089B (en) Cross-reactive staphylococcus aureus antibody
EP2847404B8 (fr) Dispositif de charnière équilibrée avec frein
EP2618018B8 (fr) Amortisseur à friction amélioré
AU2012904469A0 (en) Wastewater refinery
AU2012904042A0 (en) GGG Train
AU2012903794A0 (en) Variable transmission assembly
AU2012901927A0 (en) Jasmine Hair Oil
AU2012902222A0 (en) Change the value added tax